

ABE Technology (HK) Limited Initiates Clinical Trials in Collaboration with Local Medical Facilities

ABE Technology (HK) Limited initiates clinical trials for its AI-driven cardiac imaging, collaborating with Hong Kong medical institutions.

HONG KONG, CHINA, December 15, 2023 /EINPresswire.com/ -- [ABE Technology \(HK\) Limited](#), an innovator in healthcare technology, proudly announces the commencement of clinical trials in collaboration with esteemed medical facilities in Hong Kong. This crucial step marks a significant milestone in the development of ABE's cutting-edge AI-driven cardiac imaging technology, designed to revolutionize cardiac diagnostics.

Partnering with local medical institutions underscores ABE Technology's commitment to rigorous testing and validation of its innovative solution. The clinical trials aim to evaluate the effectiveness and reliability of the AI-driven cardiac imaging platform in diverse patient populations.

"We are excited to announce the initiation of clinical trials, a pivotal step in bringing our transformative technology closer to real-world applications. Collaborating with esteemed medical facilities in Hong Kong allows us to rigorously assess the performance and impact of our AI-driven cardiac imaging platform," said Sun Jianhong, CEO of ABE Technology (HK) Limited.

The trials will involve a comprehensive assessment of the technology's diagnostic accuracy and efficiency in detecting various cardiac conditions. ABE Technology aims to leverage insights from these trials to refine the platform further, ensuring it meets the highest standards of reliability and efficacy.

The CEO emphasised the importance of this milestone, stating, "Our collaboration with local medical facilities underscores our commitment to delivering a solution that not only meets regulatory standards but also exceeds expectations in terms of performance and impact on patient care. We believe that the success of these trials will bring us one step closer to transforming cardiac diagnostics."

ABE Technology remains dedicated to transparency throughout the clinical trial process, recognising the significance of this research in advancing healthcare technology. The company looks forward to sharing key findings as they emerge and leveraging the data gathered to

enhance the development of its AI-driven cardiac imaging platform.

About ABE Technology (HK) Limited:

ABE Technology (HK) Limited is a Hong Kong-based company dedicated to advancing healthcare through innovative technology. Specialising in AI-driven cardiac imaging solutions, ABE Technology aims to transform the landscape of cardiac diagnostics for improved patient outcomes. For more information, visit <https://www.abethealth.com>.

Michael Feng

ABE Technology (HK) Limited

+852 5819 6989

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/675260389>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.